Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Compass Therapeutics, Inc. on June 3, 2021. The filing details the final voting results for proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
The following matters were submitted to a vote of stockholders:
- Proposal No. 1: Election of Directors
- Brett Kaplan, M.D.: Elected with 42,385,503 votes For, 50,000 Withheld, and 0 Broker Non-votes.
- Julie Sunderland: Elected with 42,385,503 votes For, 50,000 Withheld, and 0 Broker Non-votes.
- Both directors were elected to serve until the 2024 Annual Meeting.
- Proposal No. 2: Ratification of Auditors
- Stockholders ratified the appointment of CohnReznick, LLP as the independent registered public accounting firm for the year ending December 31, 2021.
- Votes: 42,385,503 For, 50,000 Against, 0 Abstained, and 0 Broker Non-votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. For detailed descriptions of the proposals, the filing references the definitive proxy statement on Form DEF 14A filed on April 29, 2021.
Key Facts for Investor Verification
- Confirmation that Brett Kaplan, M.D., and Julie Sunderland were successfully re-elected to the Board of Directors.
- Verification that CohnReznick, LLP was ratified as the independent auditor for the 2021 fiscal year.
- Review of the April 29, 2021, Form DEF 14A for detailed context on director qualifications and auditor independence.